- Home
- CIGL vs XFOR Comparison
CIGL vs XFOR Comparison
Compare CIGL & XFOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CIGL
- XFOR
- Stock Information
- Founded
- CIGL 1997
- XFOR 2014
- Country
- CIGL Singapore
- XFOR United States
- Employees
- CIGL N/A
- XFOR N/A
- Industry
- CIGL Diversified Commercial Services
- XFOR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CIGL Consumer Discretionary
- XFOR Health Care
- Exchange
- CIGL Nasdaq
- XFOR Nasdaq
- Market Cap
- CIGL 145.9M
- XFOR 118.4M
- IPO Year
- CIGL 2025
- XFOR N/A
- Fundamental
- Price
- CIGL $2.97
- XFOR $1.82
- Analyst Decision
- CIGL
- XFOR Strong Buy
- Analyst Count
- CIGL 0
- XFOR 3
- Target Price
- CIGL N/A
- XFOR $72.33
- AVG Volume (30 Days)
- CIGL 736.1K
- XFOR 1.6M
- Earning Date
- CIGL 01-01-0001
- XFOR 08-07-2025
- Dividend Yield
- CIGL N/A
- XFOR N/A
- EPS Growth
- CIGL N/A
- XFOR N/A
- EPS
- CIGL N/A
- XFOR 2.16
- Revenue
- CIGL $10,490,668.00
- XFOR $31,364,000.00
- Revenue This Year
- CIGL N/A
- XFOR $1,300.08
- Revenue Next Year
- CIGL N/A
- XFOR N/A
- P/E Ratio
- CIGL N/A
- XFOR $0.84
- Revenue Growth
- CIGL N/A
- XFOR N/A
- 52 Week Low
- CIGL $2.12
- XFOR $1.38
- 52 Week High
- CIGL $31.06
- XFOR $26.96
- Technical
- Relative Strength Index (RSI)
- CIGL N/A
- XFOR 44.64
- Support Level
- CIGL N/A
- XFOR $1.38
- Resistance Level
- CIGL N/A
- XFOR $2.25
- Average True Range (ATR)
- CIGL 0.00
- XFOR 0.18
- MACD
- CIGL 0.00
- XFOR 0.10
- Stochastic Oscillator
- CIGL 0.00
- XFOR 50.57
About CIGL Concorde International Group Ltd Class A Ordinary Shares
Concorde International Group Ltd is an integrated security services provider that combines physical manpower and technology to deliver effective security solutions. The company offers a range of services to enhance security and safety: (1) i-Guarding Services; (2) Man-Guarding Services; and (3) Consultancy and Training Services. Its i-Guarding Services leverages technology to increase efficiency, with a mobile platform and cluster aggregation model of a higher skillset workforce. It has two operating segments, which are (i) security services; and (ii) training school. Key revenue is generated from Security Services.
About XFOR X4 Pharmaceuticals Inc.
X4 Pharmaceuticals Inc is a late-stage clinical biopharmaceutical company engaged in the research and development of novel therapeutics for the treatment of rare diseases and those with limited treatment options, with a focus on conditions resulting from dysfunction of the immune system. The Company's lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It has the ability to increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.